Results 51 to 60 of about 42,888 (218)

Group-specific human granulocyte antigens on a chronic myelogenous leukemia cell line with a Philadelphia chromosome marker [PDF]

, 1977
SI Drew, P. Terasaki, RJ Billing, O. J. Bergh, Jun Minowada, E. Klein   +5 more
openalex   +3 more sources

Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia

Haematologica, 2007
Five Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) patients with additional chromosome abnormalities at diagnosis have been followed during Imatinib therapy.
Alfonso Zaccaria, Anna Maria Valenti, Emilio Donti, Alessandro Gozzetti, Sonia Ronconi, Francesco Spedicato   +5 more
doaj   +1 more source

Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk

British Journal of Haematology, EarlyView.
Inherited thrombocytopenia (IT) caused by germline variants in RUNX1, ETV6 or ANKRD26 carries a high risk of developing haematological malignancy. This study examined the clinical, platelet and molecular characteristics of 66 patients with these conditions, who carried 24 distinct genetic variants in the corresponding genes.
Ana Marín‐Quílez, Ana Sánchez‐Fuentes, Ana Zamora‐Cánovas, Pedro Luis Gómez‐González, Lorena Diaz‐Ajenjo, Rocío Benito, Agustín Rodríguez‐Alén, Teresa Sevivas, Thais Murciano, Laura Murillo, Nora V. Butta, Nuria Revilla, Rosa Campos, Paola Escribano, Jordi Esteve, Nuria Fernández‐Mosteirin, Francisca Ferrer‐Marín, Laura Hernández, Jorge Huerta‐Aragonés, Antonio León, Mónica López‐Duarte, Eugenia López, Mónica Martín‐Salces, Meritxell Nomdedeu, Raquel Oña, Irene Peláez‐Pleguezuelos, Fernando Ramos, Elena Sebastián, Claudia Serrano, Cristina Sierra‐Aisa, Rosa Vidal‐Laso, José Ramón González‐Porras, María Luisa Lozano, José María Bastida, José Rivera   +34 more
wiley   +1 more source

Reliability Evaluation of Fluorescence In Situ Hybridization (FISH) and G-Banding on Bone Marrow and Peripheral Blood Cells in Chronic Myelogenous Leukemia Patients [PDF]

Cell Journal, 2015
Chronic myeloid leukemia (CML) is a myeloproliferative disease. The cytogenetic hallmark of CML is Philadelphia (Ph) chromosome. This study aimed to diagnose suspected CML patients, to monitor CML patients under therapy using cytogenetic and ...
Soheila Manaflouyan Khajehmarjany, Seyed Ali Rahmani, Seyed Hadi Chavoshi, Ali Esfahani, Ali Akbar Movassaghpour Akbari   +4 more
doaj  

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

Haematologica, 2011
Background Allogeneic hematopoietic cell transplantation is a potentially curative treatment for patients with acute lymphoblastic leukemia. However, the majority of older adults with acute lymphoblastic leukemia are not candidates for myeloablative ...
Ron Ram, Rainer Storb, Brenda M. Sandmaier, David G. Maloney, Ann Woolfrey, Mary E. D. Flowers, Michael B. Maris, Ginna G. Laport, Thomas R. Chauncey, Thoralf Lange, Amelia A. Langston, Barry Storer, George E. Georges   +12 more
doaj   +1 more source

Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions

European Journal of Haematology, EarlyView.
ABSTRACT Chronic myeloid leukemia (CML) has undergone a transformation from a fatal disease to a chronic, manageable condition with the advent of tyrosine kinase inhibitors (TKIs), particularly imatinib. This shift has significantly improved survival rates, and for some patients, achieving deep molecular response (DMR) has made treatment‐free remission
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Nicola Amodio, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Fortunato Morabito, Massimo Gentile   +9 more
wiley   +1 more source

The Role of Hematopoietic Stem-Cell Transplantation in First Remission in Pediatric Acute Lymphoblastic Leukemia: A Narrative Review

Journal of Pediatrics Review, 2017
Context Survival after allogeneic hematopoietic stem-cell transplantation (HSCT) for children with hematologic malignancies including acute lymphoblastic leukemia (ALL) continues to improve in part due to advancement in HLA typing and enhanced ...
Neel S. Bhatt, Rachel Phelan, Michael J. Burke   +2 more
doaj   +2 more sources

Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine

European Journal of Haematology, EarlyView.
ABSTRACT JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers.
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, Bernhard Heinrich, Jürgen Wehmeyer, Eyck von der Heyde, Hans Tesch, Benedikt Gröschl, Petra Bachhuber, Susanne Großer, Michael Koehler, Heike L. Pahl   +15 more
wiley   +1 more source

Ten‐Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS‐TILDA)

Journal of Intellectual Disability Research, EarlyView.
ABSTRACT Background People with intellectual disability are frequently exposed to medication with anticholinergic activity. In the general population, the long‐term exposure to anticholinergics has been associated with declines in both physical and cognitive function.
Lamya Al Shuhaimi, Ian D. Maidment, Martin C. Henman, Phyo K. Myint, Juliette O'Connell, Caitríona Ryan, Philip McCallion, Mary McCarron, Maire O'Dwyer   +8 more
wiley   +1 more source

Central mechanisms of emesis: A role for GDF15

Neurogastroenterology &Motility, Volume 37, Issue 3, March 2025.
Abstract Background Nausea and emesis are ubiquitously reported medical conditions and often present as treatment side effects along with polymorbidities contributing to detrimental life‐threatening outcomes, such as poor nutrition, lower quality of life, and unfavorable patient prognosis.
Tito Borner, Allison M. Pataro, Bart C. De Jonghe   +2 more
wiley   +1 more source